Abstract
Purpose
P-selectin receptor is expressed in platelets and endothelial cells in a cell-activation-dependent manner. Platelet P-selectin (CD62) levels may become elevated in a number of vasoocclusive diseases, including arteriosclerosis, atherothrombosis, and diabetes mellitus (DM). Nonarteritic anterior ischemic optic neuropathy (NAION) is associated with a sudden loss of vision due to the vascular insufficiency of ciliary arteries supplying the optic nerve. In this study, our aim was to investigate the presence of increased platelet reactivity in the development of NAION.
Methods
Twenty-one NAION patients, 39 healthy control subjects, and 44 patients suffering from diabetes mellitus (DM) were examined in our case-control, pilot study. Platelet activation was investigated by flow cytometric analysis of the mean fluorescence intensity (MFI) of CD62 on platelets. These results were compared among the different study groups.
Results
NAION patients showed considerably although not signifactly (p = 0.2017) higher P-selectin MFI values (71.98 ± 40.30) versus healthy subjects (55.48 ± 20.95), insulin-dependent DM patients (50.02 ± 13.08), and non-insulin-dependent DM subjects (54.72 ± 24.74). However, logistic regression analysis resulted in a statistically significant adjusted effect on the odds of NAION when CD62 MFI values were logarithmically transformed (OR: 3.86, 95 % CI: 1.10 to 13.53, p = 0.0346).
Conclusion
Elevated platelet CD62 positivity may be related to NAION, suggesting a possible role of enlarged platelet activity in the generation of this type of ischemic optic neuropathy.
Similar content being viewed by others
References
Kappelmayer J, Nagy B Jr, Miszti-Blasius K, Hevessy Z, Setiadi H (2004) The emerging value of P-selectin as a disease marker. Clin Chem Lab Med 42:475–486
Furie B, Furie BC (2004) Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 10:171–178
Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD (2000) Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A 97:13835–13840
Michelson AD, Barnard MR, Hechtman HB, MacGregor H, Connolly RJ, Loscalzo J, Valeri CR (1996) In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A 93:11877–11882
Amrani DL, Stojanovic L, Mosesson MN, Shalev Y, Mosesson MW (1995) Development of a whole platelet ELISA to detect circulating activated platelets. J Lab Clin Med 126:603–611
Minamino T, Kitakaze M, Asanuma H, Ueda Y, Koretsune Y, Kuzuya T, Hori M (1999) Plasma adenosine levels and platelet activation in patients with atrial fibrillation. Am J Cardiol 83:194–198
Nagy B Jr, Csongradi E, Bhattoa HP, Balogh I, Blasko G, Paragh G, Kappelmayer J, Kaplar M (2007) Investigation of Thr715Pro P-selectin gene polymorphism and soluble P-selectin levels in type 2 diabetes mellitus. Thromb Haemost 98:186–191
Marquardt L, Ruf A, Mansmann U, Winter R, Schuler M, Buggle F, Mayer H, Grau AJ (2002) Course of platelet activation markers after ischemic stroke. Stroke 33:2570–2574
Burger PC, Wagner DD (2003) Platelet P-selectin facilitates atherosclerotic lesion development. Blood 101:2661–2666
Jilma B, Fasching P, Ruthner C, Rumplmayr A, Ruzicka S, Kapiotis S, Wagner OF, Eichler HG (1996) Elevated circulating P-selectin in insulin dependent diabetes mellitus. Thromb Haemost 76:328–332
Chong BH, Murray B, Berndt MC, Dunlop LC, Brighton T, Chesterman CN (1994) Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood 83:1535–1541
Katayama M, Handa M, Araki Y, Ambo H, Kawai Y, Watanabe K, Ikeda Y (1993) Soluble P-selectin is present in normal circulation and its plasma level is elevated in patients with thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome. Br J Haematol 84:702–710
Chung I, Choudhury A, Patel J, Lip GY (2009) Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure. Ann Med 41:45–51
Nagy V, Facsko A, Takacs L, Balazs E, Berta A, Balogh I, Edes I, Czuriga I, Pfliegler G (2004) Activated protein C resistance in anterior ischaemic optic neuropathy. Acta Ophthalmol Scand 82:140–143
Nagy V, Steiber Z, Takacs L, Vereb G, Berta A, Bereczky Z, Pfliegler G (2006) Trombophilic screening for nonarteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 244:3–8
Hayreh SS (1974) Anterior ischaemic optic neuropathy. I. Terminology and pathogenesis. Br J Ophthalmol 58:955–963
Hayreh SS, Joos KM, Podhajsky PA, Long CR (1994) Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 118:766–780
Hayreh SS, Podhajsky PA, Zimmerman B (1997) Nonarteritic anterior ischemic optic neuropathy: time of onset of visual loss. Am J Ophthalmol 124:641–647
Beck RW, Servais GE, Hayreh SS (1987) Anterior ischemic optic neuropathy. IX. Cup-to-disc ratio and its role in pathogenesis. Ophthalmology 94:1503–1508
Beri M, Klugman MR, Kohler JA, Hayreh SS (1987) Anterior ischemic optic neuropathy. VII. Incidence of bilaterality and various influencing factors. Ophthalmology 94:1020–1028
Mojon DS, Hedges TR 3rd, Ehrenberg B, Karam EZ, Goldblum D, Abou-Chebl A, Gugger M, Mathis J (2002) Association between sleep apnea syndrome and nonarteritic anterior ischemic optic neuropathy. Arch Ophthalmol 120:601–605
Salomon O, Huna-Baron R, Kurtz S, Steinberg DM, Moisseiev J, Rosenberg N, Yassur I, Vidne O, Zivelin A, Gitel S, Davidson J, Ravid B, Seligsohn U (1999) Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy. Ophthalmology 106:739–742
Salomon O, Rosenberg N, Steinberg DM, Huna-Baron R, Moisseiev J, Dardik R, Goldan O, Kurtz S, Ifrah A, Seligsohn U (2004) Nonarteritic anterior ischemic optic neuropathy is associated with a specific platelet polymorphism located on the glycoprotein Ibalpha gene. Ophthalmology 111:184–188
Hayreh SS, Podhajsky PA, Zimmerman B (1998) Ocular manifestations of giant cell arteritis. Am J Ophthalmol 125:509–520
Hollander JE, Muttreja MR, Dalesandro MR, Shofer FS (1999) Risk stratification of emergency department patients with acute coronary syndromes using P-selectin. J Am Coll Cardiol 34:95–105
Robless PA, Okonko D, Lintott P, Mansfield AO, Mikhailidis DP, Stansby GP (2003) Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg 25:16–22
Weikert U, Kuhl U, Schultheiss HP, Rauch U (2002) Platelet activation is increased in patients with cardiomyopathy: myocardial inflammation and platelet reactivity. Platelets 13:487–491
Zeiger F, Stephan S, Hoheisel G, Pfeiffer D, Ruehlmann C, Koksch M (2000) P-Selectin expression, platelet aggregates, and platelet-derived microparticle formation are increased in peripheral arterial disease. Blood Coagul Fibrinolysis 11:723–728
Body R, Pemberton P, Ali F, McDowell G, Carley S, Smith A, Mackway-Jones K (2011) Low soluble P-selectin may facilitate early exclusion of acute myocardial infarction. Clin Chim Acta 412:614–618
Grau AJ, Ruf A, Vogt A, Lichy C, Buggle F, Patscheke H, Hacke W (1998) Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia. Thromb Haemost 80:298–301
Zeller JA, Tschoepe D, Kessler C (1999) Circulating platelets show increased activation in patients with acute cerebral ischemia. Thromb Haemost 81:373–377
Turkoz Y, Evereklioglu C, Ozkiris A, Mistik S, Borlu M, Ozerol IH, Duygulu F, Ilhan O (2005) Serum levels of soluble P-selectin are increased and associated with disease activity in patients with Behcet’s syndrome. Mediat Inflamm 2005:237–241
Kupersmith MJ, Frohman L, Sanderson M, Jacobs J, Hirschfeld J, Ku C, Warren FA (1997) Aspirin reduces the incidence of second eye NAION: a retrospective study. J Neuroophthalmol 17:250–253
Newman NJ, Scherer R, Langenberg P, Kelman S, Feldon S, Kaufman D, Dickersin K, Ischemic Optic Neuropathy Decompression Trial Research Group (2002) The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol 134:317–328
Atkins EJ, Bruce BB, Newman NJ, Biousse V (2010) Treatment of nonarteritic anterior ischemic optic neuropathy. Surv Ophthalmol 55:47–63
Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E, Harder S (2003) Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther 73:232–241
Moshfegh K, Redondo M, Julmy F, Wuillemin WA, Gebauer MU, Haeberli A, Meyer BJ (2000) Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol 36:699–705
Author information
Authors and Affiliations
Corresponding author
Additional information
Valeria Nagy and Bence Kolozsvari equally contributed to this paper as first authors.
The authors have no conflict of interest in this study. This paper has not been published or submitted for publication elsewhere.
Rights and permissions
About this article
Cite this article
Nagy, V., Kolozsvari, B., Balogh, Z. et al. Increased level of platelet P-selectin in nonarteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 251, 917–922 (2013). https://doi.org/10.1007/s00417-012-2196-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-012-2196-0